The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Chia,
As always , we should take the prospects of SNG001 with optimism but we still need P3 confirmation for Covid , we need to finish the P2b trial in COPD before doing a P3 in COPD
As for asthma and any other indication well the journey will be much longer
Eyes to the stars but feet on the ground ......
Btw , we got the P3 trial and the placing ....as predicted
Gollum, I am interested why you think J&J in particular?
I happen to agree, but am very interested in your thinking.
I have not read any lies on here this evening...just opinions....
I disagree with posters who come on here and spout nonsense and tell lies!
Here is my part of the wild speculation
This has got Johnson & Johnson Written all over it for a JV
oilornothing.......What do you disagree with.....???
I do not have a problem with posters who have a different view,
but name calling is pretty childish!
Don't know Org....But in light of the Pandemic and the urgency
for treatments I believe they will regularly monitor the trial and
if as I expect the results are overwhelming I think they intervene...IMHO!
Let's face it, none of us really know what the SP could be in the event of successful trial results.
If phase 3 results match phase 2 then it could be like nothing you've ever seen. Look at how well Novacyt is performing from selling tests - a treatment and a test are not even comparable.
Did any of us think a year ago we would see a lockdown scenario? Pop up hospitals in major cities? Closed borders etc? Course not - the scale of this pandemic means an effective treatment would be invaluable. If you find one then attach whatever price you want to it and someone may pay.
Yes....!
Numis have put that target on the board.....(£50)
If P3 is successful....I think you could reasonably say
that SNG001 will become a treatment for COPD and Asthma which are
both huge markets, and most likely other conditions too, so £50 is
possible! IMHO if we get FDA approval for Covid 19....which I believe will
come before the end of our P3 trial as I think the interim results will be
strong enough to identify its efficacy..Then I think a bid will be made by a major pharma!
RM knows the potential, he made that clear in the last Proactive interview....So
Numis have set the figure probably in discussion with RM and I do not
think offers that are significantly lower will be of interest...Yes we will get to vote
on any potential offer...But if the RNS says the board think it is too low then
I expect it woud be rejected by shareholders...IMHO!!
There is only one thing worse than paying tax and that is not paying tax. Hope the take over is in shares and not cash and hey presto no problem
Wow I've seen some wild speculation on these LSE boards in my time, but if this reaches £100 SP I'll eat every single hat I ever see, in perpetuity.
@Ghia... I think that most Synners would entirely agree. I also think that approval to use SNG001 not too far off. This then could lead to a T/O, probably in the £40/50 region, maybe even within the current tax year.
If things worked out this way this could give me a personal tax problem, and that being that whilst most of my SYN shares are in ISA's, I still have about 80K (with an average sp of 80p) in a non-ISA holding. An early T/O (@good price) would be nice, but....... a build up to a sp of £100+ would be even better, and might give me (& others with my predicament) time to figure out how not to give a great chunk of capital gains back to an increasingly desperate tenant of No11 !!!
Ghia. Always good to read your posts.
I know I bang on about SNG001 having a multitude of use cases.
For me it’s the key to why this drug will be a multi billion dollar treatment.
It was very interesting to hear RM discuss the avenues a future owner of the drug may choose to go down.
On top of the obvious, Covid, COPD, Asthma, prophylactic his mention of Premature Babies really caught my attention.
Some serious confidence in the safety profile of the drug right there.